on another note..., page-15

"11/ 12 patients went on to receive additional salvage therapy after completing the PAT-SM6 clinical
trial. Remarkably, 7/ 11 patients responded very positively with a partial response (PR) while 3
others responded with SD indicating that PAT-SM6 treatment may make cancer cells more sensitive
to killing by other chemotherapeutics".

Did anyone not read that part?

11th 2013:

"The eleven patients (9 male and 2 female, median age 71 years) had, on average, received five prior lines of therapy including autologous stem cell transplantation and other novel marketed compounds including Velcade and Revlimid. Therapeutic options for such patients are usually limited to clinical trials and their median overall survival is around nine months".

PAB achieved a partial response in combination after a safety trial with maybe 1/3 the dosage that could be used safely based on other antibodies including the comparison given with Elotuzumab.

Could this lead to a drug that could be sold?

Could this lead to one of the highly competitive drugs on the market getting a larger market share?


The stock is simply not behaving as it should so its being sold.Its an open market.

The stock goes down on good announcements historically so why would anyone buy it?